- Why in news
- On 16 July 2026, NITI Aayog launched a roadmap to make India a leading bioeconomy powerhouse by 2035. Minister Jitendra Singh released it in New Delhi.
- What it is
- The Roadmap for Building India as a Leading Bioeconomy Powerhouse by 2035 is a NITI Aayog report. It was developed by the NITI Frontier Tech Hub with the Department of Biotechnology, ABLE, industry and academia. It builds on the BioE3 Policy and proposes missions and funding to scale biomanufacturing.
- Prepared by
- NITI Frontier Tech Hub developed it with the Department of Biotechnology, ABLE, industry and academia.
- Size of bioeconomy
- India's bioeconomy grew from $10 billion in 2014 to $195.3 billion in 2025, which is 4.8% of GDP.
- Targets
- The targets are $691 billion by 2035 and $2.6 trillion by 2047, with over 30 million high-value jobs.
- Growth Fund
- A proposed ₹50,000 crore BioEconomy Growth Fund would be carved out of the existing ₹1 lakh crore RDI framework.
Don’t confuse with BioE3 Policy vs this roadmap: BioE3 is a government policy for biomanufacturing and the bioeconomy. The NITI roadmap is a recommendation report that builds on it and is not itself a policy.
Reports and indices: 14 Prelims questions since 2013; they test who publishes a report and what it measures.
Why it matters
- Gives a long-term target and a mission structure for a sector that is growing quickly.
- Links AI and biology, which can lower discovery costs and improve global competitiveness.
- Covers health, agriculture, marine, pandemic preparedness and biomanufacturing together.
Problems
- The roadmap is a set of proposals. The fund and missions need government approval and money.
- Scale-up and biomanufacturing infrastructure are weak links between lab discovery and commercial products.
- Biosafety, regulation and ethics need clear rules as synthetic biology and gene therapies grow.
Way forward
- Approve the missions and the Growth Fund, with clear milestones and timelines.
- Build shared biofoundries and testing facilities, and bring in private investment.
- Set up predictable, science-based regulation and train skilled talent.
Put in your answer
Bioeconomy growth: The bioeconomy grew from $10 billion in 2014 to $195.3 billion in 2025, or 4.8% of GDP.
Six National BioMissions: These missions cover health, agriculture, industrial biotech, pandemic preparedness, blue economy and biopharma.
BioEconomy Growth Fund: A ₹50,000 crore fund is proposed for scale-up and commercialisation.
- 2025Mains GS3 · Q6How can India achieve energy independence via clean tech by 2047, and biotechnology's role?
- 2018Mains GS3 · Q15Why is biotechnology activity high in India, and how has it benefited biopharma?
- 2021Mains GS3 · Q15What applied biotechnology achievements exist, and how do they uplift poorer sections?
- 2026Prelims Q48Which statements on GenomeIndia Project, a DBT-funded genetic diversity catalogue, are correct?
UPSC’s own questions that come close to this issue, from our Prelims and Mains banks.
Prelims practice · Statements
Ours, not from a UPSC paper
Consider the following statements:
- 1.The Roadmap for Building India as a Leading Bioeconomy Powerhouse by 2035 was developed by the NITI Frontier Tech Hub in consultation with the Department of Biotechnology and the industry body ABLE.
- 2.The roadmap proposes a ₹50,000 crore BioEconomy Growth Fund as a new allocation over and above the existing ₹1 lakh crore RDI framework.
- 3.The roadmap sets a bioeconomy target of $691 billion by 2035 and $2.6 trillion by 2047.
Which of the statements given above is/are correct?
True or false?
1 of 6
Statements the way Prelims prints them. Say first, then see the fact.
1.The roadmap was developed by the NITI Frontier Tech Hub in consultation with the Department of Biotechnology and industry body ABLE.
True. NITI Frontier Tech Hub led it, with DBT and ABLE.
2.The roadmap puts India's bioeconomy at $195.3 billion in 2025, about 4.8% of GDP.
True. $195.3 billion in 2025, 4.8% of GDP.
3.The roadmap recommends six National BioMissions, including GeneIndia, One Health Grid and Marine Biotechnology.
True. Six missions, including these three.
4.The proposed BioEconomy Growth Fund of ₹50,000 crore would be a new allocation over and above the ₹1 lakh crore RDI framework.
False. It would be carved out from within the existing ₹1 lakh crore RDI framework.
5.NITI Aayog is a statutory body established by an Act of Parliament.
False. NITI Aayog was set up in 2015 by a Cabinet resolution; it is not statutory.
6.The roadmap states that it builds on the BioE3 Policy and seeks to strengthen India as a biomanufacturing hub.
True. The minister linked the roadmap to the BioE3 Policy.
Written by us from the release, not by UPSC; checked by a second model.
Mains practice
10 marks · 150 words
NITI Aayog has launched a roadmap to make India a leading bioeconomy powerhouse by 2035, proposing six National BioMissions and a ₹50,000 crore BioEconomy Growth Fund. Discuss the significance of the bioeconomy for India's growth and examine the challenges in scaling up biomanufacturing.
Worth revising until Prelims 2028: most news questions come within two years of the event.